[go: up one dir, main page]

SG10202011033QA - Phthalocyanine dye conjugates and their storage - Google Patents

Phthalocyanine dye conjugates and their storage

Info

Publication number
SG10202011033QA
SG10202011033QA SG10202011033QA SG10202011033QA SG10202011033QA SG 10202011033Q A SG10202011033Q A SG 10202011033QA SG 10202011033Q A SG10202011033Q A SG 10202011033QA SG 10202011033Q A SG10202011033Q A SG 10202011033QA SG 10202011033Q A SG10202011033Q A SG 10202011033QA
Authority
SG
Singapore
Prior art keywords
storage
phthalocyanine dye
dye conjugates
conjugates
phthalocyanine
Prior art date
Application number
SG10202011033QA
Inventor
Lewis Makings
Roger Heim
Miguel Garcia-Guzman
Eileen Chin
Deepak Yadav
Jerry Fong
Original Assignee
Rakuten Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rakuten Medical Inc filed Critical Rakuten Medical Inc
Publication of SG10202011033QA publication Critical patent/SG10202011033QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10202011033QA 2015-08-18 2016-08-18 Phthalocyanine dye conjugates and their storage SG10202011033QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562206774P 2015-08-18 2015-08-18

Publications (1)

Publication Number Publication Date
SG10202011033QA true SG10202011033QA (en) 2020-12-30

Family

ID=56801860

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202011033QA SG10202011033QA (en) 2015-08-18 2016-08-18 Phthalocyanine dye conjugates and their storage

Country Status (11)

Country Link
US (2) US11141483B2 (en)
EP (2) EP3337568B1 (en)
JP (4) JP7055742B6 (en)
CN (4) CN112494659B (en)
AU (1) AU2016308286B2 (en)
CA (1) CA2994871A1 (en)
DK (1) DK3337568T3 (en)
ES (2) ES2999358T3 (en)
NZ (1) NZ739788A (en)
SG (1) SG10202011033QA (en)
WO (1) WO2017031363A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
JP6796058B2 (en) 2014-08-08 2020-12-02 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Light-controlled removal of targets in vitro and in vivo
CN121270700A (en) 2015-08-07 2026-01-06 美国政府(由卫生和人类服务部的部长所代表) Near infrared light immunotherapy (NIR-PIT) against suppressor cells for the treatment of cancer
SG10202011033QA (en) * 2015-08-18 2020-12-30 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
JP7085995B2 (en) * 2015-08-18 2022-06-17 ラクテン・メディカル，インコーポレイテッド Compositions, Combinations and Related Methods for Photoimmunotherapy
MX393780B (en) 2017-01-17 2025-03-24 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US10682602B2 (en) * 2017-01-19 2020-06-16 National University Of Singapore Nanofibrous filter
SG11201907571WA (en) * 2017-02-23 2019-09-27 Rakuten Medical Inc Therapeutic compositions and related methods for photoimmunotherapy
RU2758128C1 (en) 2017-12-29 2021-10-26 Крафт Фудс Груп Брэндс Ллк Improved oxidation stability of oil-in-water emulsions using natural stabilisers
WO2019172110A1 (en) * 2018-03-09 2019-09-12 学校法人慈恵大学 Conjugate of antibody targeting blood vessels and photosensitizer
KR102854858B1 (en) * 2018-06-01 2025-09-03 라쿠텐 메디칼, 인크. Phthalocyanine dye conjugate composition
WO2020198293A1 (en) * 2019-03-25 2020-10-01 Northshore University Health System Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer
JP2022525791A (en) * 2019-03-26 2022-05-19 株式会社島津製作所 Photoimmunotherapy and the drugs used for it
EP3948274A1 (en) 2019-03-29 2022-02-09 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
WO2020246350A1 (en) * 2019-06-03 2020-12-10 学校法人慈恵大学 Bactericide
JP2022543611A (en) * 2019-08-07 2022-10-13 ラクテン・メディカル，インコーポレイテッド Cetuximab-IR700 conjugate compositions
US20220378949A1 (en) * 2019-10-23 2022-12-01 Manzanita Pharmaceuticals, Inc. Neurotrophin receptor binding conjugate compositions, methods of use and methods of making thereof
JP7673968B2 (en) * 2019-12-03 2025-05-09 国立大学法人東海国立大学機構 Photoantimicrobial therapy
WO2021113734A1 (en) * 2019-12-06 2021-06-10 Rakuten Medical, Inc. Methods for enhancing immunity and tumor treatment
CN114981298B (en) 2019-12-12 2024-08-20 听治疗有限责任公司 Compositions and methods for preventing and treating hearing loss
CN111057063B (en) * 2019-12-19 2022-06-14 福州大学 Phthalocyanine derivative for targeted photodynamic therapy of acute lymphocytic leukemia and preparation method thereof
US20230331804A1 (en) * 2019-12-31 2023-10-19 Fred Hutchinson Cancer Center Nanoparticle systems to stimulate and maintain immune system responsiveness at treatment sites
CN115335489B (en) * 2020-04-02 2025-08-12 爱天思株式会社 Fluorescent markers and compounds
EP4132583A4 (en) * 2020-04-10 2024-11-13 Rakuten Medical, Inc. PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS FOR THEIR USE
US20230190934A1 (en) 2020-05-14 2023-06-22 Rakuten Medical, Inc. Methods and compositions for treating a tumor
US20230204600A1 (en) * 2020-06-12 2023-06-29 National Institute Of Advanced Industrial Science And Technology Technique for controlling quality of human pluripotent stem cells using culture supernatant
JP2022014707A (en) * 2020-07-07 2022-01-20 東亞合成株式会社 Carrier peptide fragments and their uses
JP7676766B2 (en) * 2020-12-22 2025-05-15 ａｒｔｉｅｎｃｅ株式会社 Antitumor or antibacterial agents containing phthalocyanines
US20240307541A1 (en) * 2021-02-02 2024-09-19 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
CN113150774B (en) * 2021-04-30 2022-05-31 滨州学院 A near-infrared fluorescent molecular probe, its preparation method and its application in cell imaging
JPWO2023100829A1 (en) 2021-11-30 2023-06-08
CN114409663B (en) * 2022-01-28 2023-05-30 福州大学 Zinc phthalocyanine 3-chloro-6 methylbenzo [ b ] thiophene-2-carboxylic acid conjugates targeting Mcl-1 enzyme and methods of making the same
EP4477674A1 (en) 2022-02-09 2024-12-18 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
JP2025538207A (en) 2022-11-11 2025-11-26 ラクテン・メディカル，インコーポレイテッド Engineered interleukin-15 polypeptides, conjugates thereof, and uses thereof
WO2025022964A1 (en) * 2023-07-26 2025-01-30 慶應義塾 Phthalocyanine dye, method for producing same, and drug containing phthalocyanine dye
CN119431497B (en) * 2023-07-31 2025-10-21 北京大学 Photosensitizer chimera targeting PD-L1 protein and preparation method and application thereof
WO2025089339A1 (en) * 2023-10-24 2025-05-01 国立大学法人東京科学大学 Cancer treatment agent

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE547020A (en) 1955-04-20
US5494793A (en) 1986-12-15 1996-02-27 British Technology Group Usa Inc. Monomeric phthalocyanine reagents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5196005A (en) 1991-11-26 1993-03-23 Pdt Systems, Inc. Continuous gradient cylindrical diffusion tip for optical fibers and method for making
JP2805723B2 (en) * 1994-06-09 1998-09-30 アイセロ化学株式会社 Shade container for high purity chemicals
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US6667156B2 (en) 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US7521531B2 (en) 1996-08-28 2009-04-21 Immunomedics, Inc. Methods for the purification of stable radioiodine conjugates
DE19717904A1 (en) 1997-04-23 1998-10-29 Diagnostikforschung Inst Acid-labile and enzymatically cleavable dye constructs for diagnostics with near infrared light and for therapy
US6344050B1 (en) 1998-12-21 2002-02-05 Light Sciences Corporation Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
JP3699399B2 (en) 2000-01-12 2005-09-28 ヴェンタナ メディカル システムズ インコーポレイテッド Methods for determining response to cancer treatment
AU2001241433A1 (en) 2000-02-01 2001-08-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services Methods for predicting the biological, chemical, and physical properties of molecules from their spectral properties
WO2002100326A2 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
AU2002329540A1 (en) 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030031627A1 (en) 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
US20030105299A1 (en) 2001-10-17 2003-06-05 Mallinckrodt Inc. Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications
JP2003284757A (en) 2002-01-24 2003-10-07 Seputo:Kk Red light therapy unit with heater
AUPS146502A0 (en) 2002-03-28 2002-05-09 Traynor, Neil Methods and apparatus relating to improved visual recognition and safety
JP4074136B2 (en) 2002-05-29 2008-04-09 浜松ホトニクス株式会社 Fluorescence lifetime distribution image measuring apparatus and measuring method thereof
US7597876B2 (en) 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US7005518B2 (en) 2002-10-25 2006-02-28 Li-Cor, Inc. Phthalocyanine dyes
US20040120949A1 (en) 2002-11-08 2004-06-24 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20060231107A1 (en) 2003-03-07 2006-10-19 Glickman Randolph D Antibody-targeted photodynamic therapy
WO2004099375A2 (en) 2003-04-30 2004-11-18 The General Hospital Corporation Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use therof
WO2006073419A2 (en) 2004-04-01 2006-07-13 Gang Zheng Lipoprotein nanoplatforms
US8211883B2 (en) 2004-04-01 2012-07-03 Case Western Reserve University Topical delivery of phthalocyanines
JP2008511856A (en) 2004-09-03 2008-04-17 ハンツマン アドバンスト マテリアルズ （スイッツァランド） ゲーエムベーハー Composition comprising a phthalocyanine dye
CN101023084A (en) * 2004-09-03 2007-08-22 亨斯迈先进材料（瑞士）有限公司 Compositions containing phthalocyanine dyes
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
GB0504278D0 (en) 2005-03-02 2005-04-06 Khanzada Javed Personal adornment
US20130039861A1 (en) * 2005-04-06 2013-02-14 Immunomedics, Inc. Dye Conjugated Peptides for Fluorescent Imaging
US8227621B2 (en) * 2005-06-30 2012-07-24 Li-Cor, Inc. Cyanine dyes and methods of use
EP1922077A4 (en) 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US20080095699A1 (en) 2006-10-20 2008-04-24 Shiying Zheng Imaging contrast agents using nanoparticles
DE102005059338A1 (en) 2005-12-08 2007-06-14 Carl Zeiss Jena Gmbh Method and arrangement for the examination of samples
US7993927B2 (en) 2006-07-03 2011-08-09 Beth Israel Deaconess Medical Center, Inc. Histology methods
JP2010522982A (en) 2007-03-29 2010-07-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Light emitting device including an elastomer layer
GB0711560D0 (en) 2007-06-14 2007-07-25 Innova Biosciences Ltd Improvements in or relating to production of conjugates
WO2009038776A1 (en) 2007-09-18 2009-03-26 Victor Manneh Therapeutic nanoconjugates
WO2009049184A2 (en) 2007-10-12 2009-04-16 Transmolecular, Inc. Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
EP2732826B1 (en) 2008-01-18 2017-11-08 Visen Medical, Inc. Fluorescent imaging agents
KR101595138B1 (en) 2008-02-27 2016-02-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Rgd(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors
US8580520B2 (en) 2008-09-15 2013-11-12 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
GB0819594D0 (en) 2008-10-24 2008-12-03 Univ Coimbrra Process
WO2010085651A1 (en) 2009-01-23 2010-07-29 The Penn State Research Foundation In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles
US8317737B2 (en) 2009-02-25 2012-11-27 The Invention Science Fund I, Llc Device for actively removing a target component from blood or lymph of a vertebrate subject
US8167871B2 (en) 2009-02-25 2012-05-01 The Invention Science Fund I, Llc Device for actively removing a target cell from blood or lymph of a vertebrate subject
GB0904825D0 (en) 2009-03-20 2009-05-06 Photobiotics Ltd Biological materials and uses thereof
EP3427755B1 (en) 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
EP2419478B1 (en) 2009-04-17 2018-02-28 Li-Cor, Inc. Fluorescent imaging with substituted cyanine dyes
EP2459191A1 (en) 2009-07-31 2012-06-06 OSI Pharmaceuticals, LLC Mtor inhibitor and angiogenesis inhibitor combination therapy
CA2809798C (en) 2009-08-28 2018-09-18 Visen Medical, Inc. Systems and methods for tomographic imaging in diffuse media using a hybrid inversion technique
WO2011038006A1 (en) 2009-09-22 2011-03-31 Visen Medical, Inc. Systems and methods for virtual index-matching of diffusive media
GB0917054D0 (en) 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
WO2011097248A2 (en) 2010-02-02 2011-08-11 Ventana Medical Systems, Inc. Composition and method for stabilizing fluorescent particles
US20130224115A1 (en) 2010-04-01 2013-08-29 Baylor College Of Medicine Non-radioactive agents for neuroblastoma imaging
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
US20130287688A1 (en) 2010-11-18 2013-10-31 Xtuit Pharmaceuticals, Inc. Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2012076631A1 (en) 2010-12-07 2012-06-14 Spectracure Ab System and method for interstitial photodynamic light therapy in combination with photosensitizers
US20140076404A1 (en) 2010-12-15 2014-03-20 Mei-Chee Tan Ir-activated photoelectric systems
US9018367B2 (en) 2011-04-12 2015-04-28 Board Of Regents, The University Of Texas System Single stranded DNA aptamers binding NF-κB/RelA
CN103781495A (en) * 2011-07-11 2014-05-07 美国政府(由卫生和人类服务部的部长所代表) Photosensitive antibody-fluorophore conjugates
CA2847887A1 (en) 2011-09-23 2013-03-28 Li-Cor, Inc. Application of reduced dyes in imaging
SG11201401579UA (en) 2011-12-01 2014-07-30 Univ Cape Town Hpv chimaeric particle
CN102585003B (en) 2012-02-06 2017-10-31 中国科学院福建物质结构研究所 The preparation method and applications of tumor-targeted photosensitive immunoconjugate
CA2866933C (en) 2012-03-21 2020-08-18 Rheinisch-Westfalische Technische Hochschule Aachen Novel photoimmunoconjugates for use in photodynamic therapy
US20160250337A9 (en) 2012-04-17 2016-09-01 Bahman Anvari Biomedical imaging and therapy using red blood cells
EP2885006B1 (en) 2012-08-15 2018-08-08 VisEn Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
JP2016026471A (en) 2012-11-27 2016-02-18 パナソニックヘルスケア株式会社 Cell identification separation method and cell identification separation apparatus
US20140220346A1 (en) 2012-12-04 2014-08-07 Memorial Sloan-Kettering Cancer Center Modular polymer hydrogel nanoparticles and methods of their manufacture
WO2014120974A1 (en) 2013-01-30 2014-08-07 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
US9889199B2 (en) 2013-02-15 2018-02-13 Case Western Reserve University PSMA ligands and uses thereof
CA3135558A1 (en) 2013-03-13 2014-10-02 Genentech, Inc. Prevention of protein oxidation in a composition
US20140314778A1 (en) * 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
JP2016516774A (en) 2013-04-08 2016-06-09 ユニバーシティー オブ ノースキャロライナ アット チャペル ヒルＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ Photoresponsive compound
WO2014176284A1 (en) 2013-04-22 2014-10-30 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use
US10117947B2 (en) 2013-09-18 2018-11-06 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
WO2015057692A1 (en) 2013-10-14 2015-04-23 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
AR098136A1 (en) 2013-10-21 2016-05-04 Merck Patent Gmbh HETEROARILO COMPOUNDS AS BTK INHIBITORS AND USES OF THE SAME
EP3099325A4 (en) 2014-01-31 2017-10-04 The General Hospital Corporation Dba Massachusetts General Hospital Methods of treating and imaging tumor micrometastases using photoactivatable immunoconjugates
JP2017507931A (en) 2014-02-05 2017-03-23 シーダーズ−サイナイ メディカル センター Method for treating cancer and infectious diseases and therapeutic composition
US10011587B2 (en) 2014-05-15 2018-07-03 The Methodist Hospital System Multivalent ligands targeting VEGFR
US9209062B1 (en) 2014-05-28 2015-12-08 Spintrac Systems, Inc. Removable spin chamber with vacuum attachment
WO2015187651A1 (en) 2014-06-02 2015-12-10 Li-Cor, Inc. Therapeutic and diagnostic probes
JP6796058B2 (en) 2014-08-08 2020-12-02 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Light-controlled removal of targets in vitro and in vivo
CN121270700A (en) 2015-08-07 2026-01-06 美国政府(由卫生和人类服务部的部长所代表) Near infrared light immunotherapy (NIR-PIT) against suppressor cells for the treatment of cancer
SG10202011033QA (en) 2015-08-18 2020-12-30 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
JP7085995B2 (en) 2015-08-18 2022-06-17 ラクテン・メディカル，インコーポレイテッド Compositions, Combinations and Related Methods for Photoimmunotherapy
BR112018004046B1 (en) 2015-08-28 2021-09-21 The Procter & Gamble Company CATALYTIC DEHYDRATION OF HYDROXYPROPIONIC ACID AND ITS DERIVATIVES
MX376819B (en) 2016-10-25 2025-03-07 Rakuten Medical Inc LIGHT DIFFUSING DEVICES FOR USE IN PHOTOIMMUNOTHERAPY
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
SG11201907571WA (en) 2017-02-23 2019-09-27 Rakuten Medical Inc Therapeutic compositions and related methods for photoimmunotherapy
KR102103134B1 (en) 2017-07-07 2020-04-21 라쿠텐 메디칼, 인크. Light diffusing device for use in photoimmunotherapy
WO2019036249A1 (en) 2017-08-18 2019-02-21 Li-Cor, Inc. Sonodynamic therapy
US20210079112A1 (en) 2018-04-10 2021-03-18 The United States of America, as represented by the Secretary, Department of Health and Human Ser Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation
KR102854858B1 (en) 2018-06-01 2025-09-03 라쿠텐 메디칼, 인크. Phthalocyanine dye conjugate composition
EP3948274A1 (en) 2019-03-29 2022-02-09 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
US20220313822A1 (en) 2019-07-30 2022-10-06 Rakuten Medical, Inc. Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody
JP2022543611A (en) 2019-08-07 2022-10-13 ラクテン・メディカル，インコーポレイテッド Cetuximab-IR700 conjugate compositions
JP2022546546A (en) 2019-09-03 2022-11-04 ラクテン・メディカル，インコーポレイテッド Methods for treatment using phthalocyanine dye-targeting molecule conjugates
WO2021113734A1 (en) 2019-12-06 2021-06-10 Rakuten Medical, Inc. Methods for enhancing immunity and tumor treatment
US20230190934A1 (en) 2020-05-14 2023-06-22 Rakuten Medical, Inc. Methods and compositions for treating a tumor

Also Published As

Publication number Publication date
CN114699525A (en) 2022-07-05
EP3777978B1 (en) 2024-11-27
CN112494659A (en) 2021-03-16
WO2017031363A3 (en) 2017-04-20
CN108136215B (en) 2022-04-29
JP7055742B2 (en) 2022-04-18
JP2021193111A (en) 2021-12-23
ES2999358T3 (en) 2025-02-25
US11141483B2 (en) 2021-10-12
CN108136215A (en) 2018-06-08
JP6689439B2 (en) 2020-04-28
JP2018528267A (en) 2018-09-27
DK3337568T3 (en) 2021-09-27
EP3777978A1 (en) 2021-02-17
JP2023182791A (en) 2023-12-26
JP2019218374A (en) 2019-12-26
EP3337568A2 (en) 2018-06-27
AU2016308286B2 (en) 2022-04-07
ES2889904T3 (en) 2022-01-14
JP7425026B2 (en) 2024-01-30
CN112494659B (en) 2023-08-08
AU2016308286A1 (en) 2018-03-08
JP7055742B6 (en) 2022-06-07
CN114681623A (en) 2022-07-01
EP3337568B1 (en) 2021-08-04
CA2994871A1 (en) 2017-02-23
NZ739788A (en) 2023-07-28
US20190015510A1 (en) 2019-01-17
WO2017031363A2 (en) 2017-02-23
US20210401986A1 (en) 2021-12-30
US12491249B2 (en) 2025-12-09

Similar Documents

Publication Publication Date Title
SG10202011033QA (en) Phthalocyanine dye conjugates and their storage
IL265919A (en) Pyrrolobenzodiazepine conjugates
IL258248A (en) Affinity-oligonucleotide conjugates and uses thereof
IL248221B (en) Antibody-drug conjugates with high drug loading
GB201416112D0 (en) Pyrrolobenzodiazepines and conjugates thereof
EP3148583A4 (en) Phthalocyanine probes and uses thereof
PL3303778T3 (en) Improvements in energy storage
ZA201805526B (en) Pyrrolobenzodiazepine conjugates
GB201607478D0 (en) Pyrrolobenzodiazepine Conjugates
IL258759A (en) Anti-cd3-folate conjugates and their uses
GB201602359D0 (en) Pyrrolobenzodiazepine Conjugates
TWI559868B (en) Storage folder with self-arrangement
GB201716426D0 (en) Energy storage
PT3470471T (en) Methine dyes
GB201602363D0 (en) Pyrrolobenzodiazepine conjugates
IL236578A (en) Foldable parasol
GB201619490D0 (en) Pyrrolobenzodiazepine conjugates
EP3160746A4 (en) Dye microenvironment
GB201615038D0 (en) Improvements in searching technology
ZA201804329B (en) Dye
PH32016001227S1 (en) Net label
PH32016001225S1 (en) Net label
PH32016001226S1 (en) Net label
PH32016001224S1 (en) Net label
GB201611481D0 (en) Energy storage